In that regard, the prediction of acute kidney injury (AKI) in patients at risk by the combined detection of urinary “acute kidney stress” molecules tissue inhibitor of metalloprotease-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) was recently approved by the U.S. Food and Drug Administration [15,16]. Here, IGFBP7 is linked to acute kidney injury.